Editorial: Advancing therapeutic strategies for relapsed/refractory acute lymphoblastic leukemia

A first thread links targeted, low-toxicity combina5ons to effec5ve bridging before defini5ve therapy. Jin et al. report a compelling case in which a venetoclax-chidamide-azaci5dine (VCA) regimen induced rapid complete remission of extramedullary MLL-AF4 B-ALL and served as an effec5ve bridge to CD19 CAR-T therapy, with complete metabolic remission thereaYer. The case highlights how ra5onal combina5ons that target an5-apopto5c signaling and epigene5c dysregula5on can control aggressive, transplant-refractory disease while preserving performance status for subsequent cellular therapy.A second, related contribu5on evaluates Olveremba5nib in relapsed or MRD-persistent Philadelphia-chromosome-posi5ve ALL. The study reports manageable toxicity in this realworld cohort and suggests Olveremba5nib can be incorporated into future strategies for TKIresistant Ph+ disease.Taken together, the two aforemen5oned publica5ons underline a key point: newer targeted agents and biologically ra5onal combos could convert otherwise hopeless relapses into states amenable to consolida5ve cura5ve therapy.Third, sensi5ve and prac5cal monitoring tools are needed to detect relapse earlier and tailor interven5ons. Wu et al. present proteomic discovery and ELISA valida5on that iden5fy thrombospondin-1 (THBS1) and lactoferrin (LTF) as serum proteins significantly downregulated in relapsed/refractory mul5ple myeloma. Larger valida5on and prospec5ve tes5ng will be required, but the study illustrates how highthroughput proteomics can yield clinically ac5onable signatures for relapse monitoring.Finally, robust epidemiology and cohort studies remain essen5al to translate advances into popula5on-level benefit. Zhang et al.'s compara5ve analysis of pediatric lymphoblas5c lymphoma highlights substan5al differences in stage at presenta5on, use of radiotherapy, and period-specific survival-some of which may reflect pandemic-related care disrup5on. Their work reminds clinicians and trialists that biologic advances must be considered within the reali5es of staging paeerns, treatment access, and health-system stresses that vary by region and era; these factors influence both outcome and how new therapies should be implemented.Taken together, these four contribu5ons chart a coherent agenda for the next phase of progress in relapsed/refractory hematologic malignancies:• Priori5ze biology-first bridging strategies that reduce tumor burden with tolerable toxicity (targeted agents, epigene5c modifiers) so pa5ents can receive cura5ve consolida5on (cellular therapy or transplant). • Invest in minimally invasive monitoring (proteomic signatures, circula5ng markers, refined MRD assays) to detect relapse earlier and trigger preemp5ve salvage. • Build mul5na5onal, real-world datasets to understand regional differences in presenta5on, access, and outcomes and to ensure equitable implementa5on of new regimens. • Design prospec5ve trials that combine these elements: biomarker-guided entry, biology-matched bridging, and endpoints that include func5onal outcomes (ability to receive CAR-T/allo-HCT), not just short-term response. Limita5ons are intrinsic to the contribu5ons: single-pa5ent case reports and retrospec5ve series cannot establish efficacy defini5vely, and proteomic biomarkers need large, prospec5ve valida5on. S5ll, by linking mechanis5c ra5onale (why a regimen should work), pragma5c endpoints (bridging to cura5ve therapy), and popula5on context (who will benefit and under what health-system constraints), the collec5on models how transla5onal hematology can move from isolated successes to scalable improvement.We hope these ar5cles mo5vate coordinated pipelines: rapid biological characteriza5on at relapse, adap5ve low-toxicity regimens to lower burden, sensi5ve blood-based monitoring to 5me interven5ons, and mul5center trials that measure both molecular and pa5ent-centered outcomes. The future of relapsed/refractory leukemia and other hematologic malignancies lies not in any single silver bullet, but in integrated, biology-informed care pathwaysprecisely the direc5on these papers point toward.